'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

R B Raffa; J A Gudin; S Nalamachu; J V Pergolizzi Jr

doi:10.1111/jcpt.12192

'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure

J Clin Pharm Ther. 2014 Oct;39(5):455-6. doi: 10.1111/jcpt.12192. Epub 2014 Jul 29.

Authors

R B Raffa¹, J A Gudin, S Nalamachu, J V Pergolizzi Jr

Affiliation

¹ Temple University School of Pharmacy, Philadelphia, PA, USA. robert.raffa@temple.edu.

PMID: 25070498
DOI: 10.1111/jcpt.12192

Abstract

The ongoing important debate about the relative benefits/risks of COX-1 or COX-2 NSAIDs is hampered by the use of a measure of 'selectivity' that is inherently flawed. An alternative measure provides more meaningful and clinically relevant information.

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics*
Confounding Factors, Epidemiologic
Cyclooxygenase 1 / metabolism
Cyclooxygenase 2 Inhibitors / metabolism
Cyclooxygenase Inhibitors / metabolism
Humans
Inhibitory Concentration 50

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Cyclooxygenase 1